NCT03527186View on ClinicalTrials.gov

Comparative Bioavailability of Risperidone

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

March 23, 2019

Study Completion Date

April 6, 2019

Conditions
Schizophrenia
Interventions
DRUG

Risperidone ISM® 100 mg

100 mg of risperidone ISM® administered every 4 weeks

Trial Locations (2)

90806

Collaborative Neuroscience Network, Long Beach

08009

Hassman Research Institute, Berlin

All Listed Sponsors
lead

Rovi Pharmaceuticals Laboratories

INDUSTRY

NCT03527186 - Comparative Bioavailability of Risperidone | Biotech Hunter | Biotech Hunter